Author

A. S. Carlos

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Organism:human· 1

Frequent Co-Authors

A. C. Ferreira· 2 shared C. Q. Sacramento· 2 shared M. Mattos· 2 shared N. Fintelman-Rodrigues· 2 shared P. T. Bozza· 2 shared T. M. L. Souza· 2 shared A. Marttorelli· 1 shared C. C. Garcia· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. C. Ferreira

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Macrophages undergo necroptosis during severe influenza A infection and contribute to virus-associated cytokine storm

A. C. Ferreira, C. Q. Sacramento, F. S. Pereira-Dutra, N. Fintelman-Rodrigues, P. P. Silva, M. Mattos, C. S. de Freitas, A. Marttorelli, G. R. de Melo, M. C. Macedo, I. G. Azevedo-Quintanilha, A. S. Carlos, J. V. Emidio, C. C. Garcia, P. T. Bozza, , T. M. L. Souza

This study shows that IAV or HA induces necroptosis in macrophages, contributing to cytokine storm and lung injury, and that anti-TNF treatment prevents these effects.

bioRxiv · Apr 20, 2022 · PreprintImmunology

Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo

O. A. Chaves, C. Q. Sacramento, A. C. Ferreira, M. Mattos, N. Fintelman-Rodrigues, J. R. Temerozo, D. P. Pinto, G. P. E. da Silveira, L. B. da Fonseca, H. M. Pereira, A. S. Carlos, J. d. C. P. d'Avila, J. P. B. Viola, R. Q. Monteiro, L. Vazquez, , T. M. L. Souza

This study shows that atazanavir inhibits SARS-CoV-2 Mpro, effectively reducing replication of both B.1 and gamma variants in vitro and in vivo.

bioRxiv · Nov 24, 2021Pharmacology & Toxicology